Published in Ann Surg on July 01, 1994
Pivotal preclinical trial of the spheroid reservoir bioartificial liver. J Hepatol (2015) 2.40
Glucocorticoid receptor-dependent gene regulatory networks. PLoS Genet (2005) 2.19
Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol (2013) 1.49
Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg (1997) 1.38
A multi-tissue type genome-scale metabolic network for analysis of whole-body systems physiology. BMC Syst Biol (2011) 1.37
Hepatic tissue engineering: from transplantation to customized cell-based liver directed therapies from the laboratory. J Cell Mol Med (2007) 1.18
Effects of a bioartificial liver support system on acetaminophen induced acute liver failure canines. World J Gastroenterol (1999) 1.12
Cell and tissue engineering for liver disease. Sci Transl Med (2014) 1.08
Extracorporeal perfusion for the treatment of acute liver failure. Ann Surg (2000) 0.96
State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. ALTEX (2014) 0.94
Cultivation of human liver cell lines with microcarriers acting as biological materials of bioartificial liver. World J Gastroenterol (1999) 0.89
Development and characterization of a hybrid bioartificial liver using primary hepatocytes entrapped in a basement membrane matrix. Dig Dis Sci (2001) 0.89
Novel immortalized human fetal liver cell line, cBAL111, has the potential to differentiate into functional hepatocytes. BMC Biotechnol (2009) 0.87
Long-term culture and expansion of primary human hepatocytes. Nat Biotechnol (2015) 0.87
Development and perspectives of perfusion treatment for liver failure. Surg Today (2005) 0.86
A theoretical approach to zonation in a bioartificial liver. Biotechnol Bioeng (2011) 0.83
Definition and validation of operating equations for poly(vinyl alcohol)-poly(lactide-co-glycolide) microfiltration membrane-scaffold bioreactors. Biotechnol Bioeng (2010) 0.83
A strategy to determine operating parameters in tissue engineering hollow fiber bioreactors. Biotechnol Bioeng (2011) 0.81
Liver progenitor cell line HepaRG differentiated in a bioartificial liver effectively supplies liver support to rats with acute liver failure. PLoS One (2012) 0.80
Stem cell differentiation and human liver disease. World J Gastroenterol (2012) 0.79
Hepatic tissue engineering using scaffolds: state of the art. Avicenna J Med Biotechnol (2009) 0.78
Cell biology is different in small volumes: endogenous signals shape phenotype of primary hepatocytes cultured in microfluidic channels. Sci Rep (2016) 0.77
Bioartificial liver support for fulminant hepatic failure. World J Gastroenterol (1999) 0.75
Immortalization of Human Fetal Hepatocyte by Ectopic Expression of Human Telomerase Reverse Transcriptase, Human Papilloma Virus (E7) and Simian Virus 40 Large T (SV40 T) Antigen Towards Bioartificial Liver Support. J Clin Exp Hepatol (2014) 0.75
Clinical translation of bioartificial liver support systems with human pluripotent stem cell-derived hepatic cells. World J Gastroenterol (2017) 0.75
Preparation of isolated rat liver cells. Methods Cell Biol (1976) 17.96
Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science (1980) 13.44
Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature (1979) 6.76
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis (1993) 1.84
Development of a hybrid bioartificial liver. Ann Surg (1993) 1.57
Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J (1990) 1.52
UDP-glucuronosyltransferases. Pharmacol Ther (1989) 1.47
Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology (1992) 1.26
Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther (1989) 1.23
Growth and hepatospecific gene expression of human hepatoma cells in a defined medium. In Vitro Cell Dev Biol (1987) 1.22
Modulation of the liver specific phenotype in the human hepatoblastoma line Hep G2. In Vitro Cell Dev Biol (1989) 1.19
Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology (1993) 1.11
Drug metabolism by the human hepatoma cell, Hep G2. Biochem Biophys Res Commun (1987) 1.11
HepG2. A human hepatoblastoma cell line exhibiting defects in bile acid synthesis and conjugation. J Biol Chem (1986) 1.06
Human hepatoma cells secrete single chain factor X, prothrombin, and antithrombin III. Blood (1984) 1.05
Improved liver function following treatment with an extracorporeal liver assist device. Artif Organs (1993) 1.04
Hepatocyte function in a hollow fiber bioreactor: a potential bioartificial liver. J Surg Res (1992) 0.97
Induction of drug metabolizing enzymes in human liver cell line Hep G2. FEBS Lett (1985) 0.97
Assessment of artificial liver support technology. Cell Transplant (1992) 0.95
Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries. Trans Am Soc Artif Intern Organs (1975) 0.95
Neoplastic transformation and lineage switching of rat liver epithelial cells by retrovirus-associated oncogenes. Mol Carcinog (1988) 0.95
Use of a novel bioartificial liver in a patient with acute liver insufficiency. Surgery (1993) 0.94
HepG2 cells: an in vitro model for P450-dependent metabolism of acetaminophen. Biochem Biophys Res Commun (1993) 0.91
Artificial liver: a forthcoming attraction. Hepatology (1993) 0.90
Mixed function oxidase and UDP-glucuronyltransferase activities in the human Hep G2 hepatoma cell line. Biochem Pharmacol (1988) 0.90
Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells. Biochem Biophys Res Commun (1992) 0.90
The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands. Pharmacol Rev (1991) 0.88
Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metab Dispos (1993) 0.87
Characterization of a transforming N-ras gene in the human hepatoma cell line Hep G2: additional evidence for the importance of c-myc and ras cooperation in hepatocarcinogenesis. Cancer Res (1990) 0.87
The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived Hep G2 cell line. FEBS Lett (1988) 0.87
Differential induction of human liver UDP-glucuronosyltransferase activities by phenobarbital-type inducers. Biochem Pharmacol (1987) 0.86
Bioartificial liver using hepatocytes on biosilon microcarriers: treatment of chemically induced acute hepatic failure in rats. Artif Organs (1991) 0.85
Variation in drug-metabolizing enzyme activities during the growth of human Hep G2 hepatoma cells. Xenobiotica (1990) 0.84
Immunoprotection of xenocytes in a hollow fiber bioartificial liver. ASAIO J (1993) 0.84
Extracorporeal application of a gel-entrapment, bioartificial liver: demonstration of drug metabolism and other biochemical functions. Cell Transplant (1994) 0.83
Long-term cultures of adult mammalian hepatocytes in hollow fibers as the cellular component of extracorporeal (hybrid) liver assist devices. Artif Organs (1992) 0.83
Hepatocyte culture systems for artificial liver support: implications for critical care medicine (bioartificial liver support). Crit Care Med (1992) 0.81
A hybrid artificial liver system. Function of cultured monolayer pig hepatocytes in plasma from hepatic failure patients. ASAIO Trans (1992) 0.80
Use of hepatocytes in adhesion and suspension cultures for liver support bioreactors. Int J Artif Organs (1989) 0.80
Mammalian hepatocytes as a foundation for treatment in human liver failure. J Cell Biochem (1991) 0.80
Demonstration of biochemical function by extracorporeal xenohepatocytes in an anhepatic animal model. Transplant Proc (1993) 0.80
Culturing of primary hepatocytes as entrapped aggregates in a packed bed bioreactor: a potential bioartificial liver. In Vitro Cell Dev Biol (1993) 0.80
Induction and activity of several isoenzymes of cytochrome P-450 in primary cultures of rat hepatocytes, in comparison with in vivo data. Mol Toxicol (1989) 0.79
Overcoming retention time shifts as a source of error in HPLC analysis. J Chromatogr Sci (1987) 0.78
Metabolism of lidocaine by purified rat liver microsomal cytochrome P-450 isozymes. Biochem Pharmacol (1989) 0.78
Does a porcine hepatocyte hybrid artificial liver prolong the survival time of anhepatic rabbits? ASAIO J (1993) 0.78
Variant protein patterns in hepatomas and transformed liver cell lines as determined by high resolution two-dimensional gel electrophoresis (2DE). Carcinogenesis (1992) 0.78
Selection of variant hepatoma cells in liver-specific growth media: regulation at the mRNA level. Differentiation (1992) 0.77
Liver assist devices (LADs) will not be used to treat fulminant hepatic failure (FHF), but its consequences, namely hepatic encephalopathy (HE) Artif Organs (1993) 0.77
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 3.48
Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. JAMA (1994) 2.71
Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet (1979) 2.71
Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med (1995) 2.63
Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg (1991) 2.24
Preoperative optimization of cardiovascular hemodynamics improves outcome in peripheral vascular surgery. A prospective, randomized clinical trial. Ann Surg (1991) 2.21
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res (2000) 1.81
Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A (2000) 1.75
Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem (2000) 1.63
Physiological and metabolic correlations in human sepsis. Invited commentary. Surgery (1979) 1.58
Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene (2006) 1.53
Progressive necrotizing surgical infections--a unified approach. J Trauma (1981) 1.51
Pulmonary artery catheterization. Can there be an integrated strategy for guideline development and research promotion? JAMA (1993) 1.51
Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS (2000) 1.45
Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J Pediatr (1992) 1.42
Urinary urea nitrogen: too insensitive for calculating nitrogen balance studies in surgical clinical nutrition. JPEN J Parenter Enteral Nutr (1991) 1.42
Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors. J Virol (1997) 1.40
Retroviral recombination rates do not increase linearly with marker distance and are limited by the size of the recombining subpopulation. J Virol (1998) 1.34
The hepatic failure of sepsis: cellular versus substrate. Surgery (1979) 1.32
Applied nutrition in ICU patients. A consensus statement of the American College of Chest Physicians. Chest (1997) 1.29
Effect of pH on disintegration and dissolution of ketoconazole tablets. Am J Hosp Pharm (1983) 1.29
Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother (1981) 1.27
Multiple steady states with distinct cellular metabolism in continuous culture of mammalian cells. Biotechnol Bioeng (2000) 1.27
Hypermetabolism, organ failure, and metabolic support. Surgery (1987) 1.26
Late development of hydrothorax and hydromediastinum in patients with central venous catheters. Crit Care Med (1982) 1.23
Cultivation of mammalian cells on macroporous microcarriers. Enzyme Microb Technol (1992) 1.23
Correlated template-switching events during minus-strand DNA synthesis: a mechanism for high negative interference during retroviral recombination. J Virol (1998) 1.21
Concentration-controlled zidovudine therapy. Clin Pharmacol Ther (1998) 1.20
Branched chains support postoperative protein synthesis. Surgery (1982) 1.18
Killed Escherichia coli stimulates macrophage-mediated alterations in hepatocellular function during in vitro coculture: a mechanism of altered liver function in sepsis. Infect Immun (1985) 1.16
Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J (2002) 1.15
Septic autocannibalism. A failure of exogenous nutritional support. Ann Surg (1980) 1.13
Mouse mammary tumor virus: specific methylation patterns of proviral DNA in normal mouse tissues. J Virol (1984) 1.13
High viable cell concentration fed-batch cultures of hybridoma cells through on-line nutrient feeding. Biotechnol Bioeng (1995) 1.13
Relative rates of retroviral reverse transcriptase template switching during RNA- and DNA-dependent DNA synthesis. J Virol (1998) 1.12
Micropatterning gradients and controlling surface densities of photoactivatable biomolecules on self-assembled monolayers of oligo(ethylene glycol) alkanethiolates. Chem Biol (1997) 1.11
Evolution of the bioartificial liver: the need for randomized clinical trials. Am J Surg (1993) 1.11
Mechanistics of formation and ultrastructural evaluation of hepatocyte spheroids. In Vitro Cell Dev Biol Anim (1996) 1.11
A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr (1998) 1.10
Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther (1979) 1.08
Branched chain metabolic support. A prospective, randomized, double-blind trial in surgical stress. Ann Surg (1984) 1.07
Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother (2000) 1.07
The systemic septic response: does the organism matter? Crit Care Med (1980) 1.07
Selective gut decontamination reduces nosocomial infections and length of stay but not mortality or organ failure in surgical intensive care unit patients. Arch Surg (1992) 1.06
On-line monitoring of hybridoma cell growth using a laser turbidity sensor. Biotechnol Bioeng (1992) 1.05
Distinct patterns of cyclin D1 regulation in models of liver regeneration and human liver. Biochem Biophys Res Commun (1995) 1.04
Selective detection of Mycoplasma fermentans by polymerase chain reaction and by using a nucleotide sequence within the insertion sequence-like element. J Clin Microbiol (1992) 1.04
Precursor flux control through targeted chromosomal insertion of the lysine epsilon-aminotransferase (lat) gene in cephamycin C biosynthesis. J Bacteriol (1993) 1.04
The role of actin filaments and microtubules in hepatocyte spheroid self-assembly. Cell Motil Cytoskeleton (2001) 1.03
Hemodynamic, respiratory, and metabolic effects of laparoscopic cholecystectomy. Am J Surg (1993) 1.03
Metabolism during hepatic transplantation: indicators of allograft function. Surgery (1984) 1.02
Concise review of the cytochrome P450s and their roles in toxicology. Toxicol Sci (1999) 1.02
Influence of obesity on drug disposition. Clin Pharm (1987) 1.02
A model for reimplantation and transplantation of a complex organ: the rat hind limb. J Surg Res (1978) 1.01
Effects of homology length in the repeat region on minus-strand DNA transfer and retroviral replication. J Virol (2001) 1.00
Paranasal sinusitis: a common complication of nasotracheal intubation in neurosurgical patients. Neurosurgery (1985) 1.00
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884. AIDS (2000) 0.99
Regulation of murine splenocyte responses by heparan sulfate. J Immunol (1991) 0.99
Multiple systems organ failure: I. The basal state. J Trauma (1981) 0.99
Fatty acid intake and Kupffer cell function: fish oil alters eicosanoid and monokine production to endotoxin stimulation. Surgery (1988) 0.99
Utilization of nonhomologous minus-strand DNA transfer to generate recombinant retroviruses. J Virol (1997) 0.99
Efficient assembly of rat hepatocyte spheroids for tissue engineering applications. Biotechnol Bioeng (1996) 0.99
Gel-entrapment bioartificial liver therapy in galactosamine hepatitis. J Surg Res (1995) 0.98
Hepatocyte function in a hollow fiber bioreactor: a potential bioartificial liver. J Surg Res (1992) 0.97
Utilization of nonviral sequences for minus-strand DNA transfer and gene reconstitution during retroviral replication. J Virol (2000) 0.97
Indinavir plasma protein binding in HIV-1-infected adults. AIDS (2000) 0.97
Correlations between metabolic and cardiopulmonary measurements in patients after trauma, general surgery, and sepsis. J Trauma (1979) 0.97
High density culture of mammalian cells with dynamic perfusion based on on-line oxygen uptake rate measurements. Cytotechnology (1994) 0.96
Nonreciprocal pseudotyping: murine leukemia virus proteins cannot efficiently package spleen necrosis virus-based vector RNA. J Virol (1998) 0.96
Endotoxin modulation of hepatocyte secretory and cellular protein synthesis is mediated by Kupffer cells. Arch Surg (1988) 0.96
Formation of porcine hepatocyte spheroids for use in a bioartificial liver. Cell Transplant (1995) 0.95
Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Antimicrob Agents Chemother (1982) 0.95
Alteration of mammalian cell metabolism by dynamic nutrient feeding. Cytotechnology (1997) 0.95
Effect of glucose on the cultivation of mammalian cells. Dev Biol Stand (1987) 0.94
On-line characterization of a hybridoma cell culture process. Biotechnol Bioeng (1994) 0.94
Evaluation of a hepatocyte-entrapment hollow fiber bioreactor: a potential bioartificial liver. Biotechnol Bioeng (1993) 0.94
Modulation of macrophage and B cell function by glycosaminoglycans. J Leukoc Biol (1999) 0.94
Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs. J Med Chem (1997) 0.94
Effect of the murine leukemia virus extended packaging signal on the rates and locations of retroviral recombination. J Virol (2000) 0.93
Kinetic study of hybridoma cell growth in continuous culture. I. A model for non-producing cells. Biotechnol Bioeng (1991) 0.93
Nitrogen retention in critically ill patients is proportional to the branched chain amino acid load. Crit Care Med (1983) 0.93
Enhanced survival during murine gram-negative bacterial sepsis by use of a murine monoclonal antibody. Arch Surg (1985) 0.92
The nucleocapsid domain is responsible for the ability of spleen necrosis virus (SNV) Gag polyprotein to package both SNV and murine leukemia virus RNA. J Virol (1999) 0.92
Evidence based critical care medicine; what is it and what can it do for us? Evidence Based Medicine in Critical Care Group. Crit Care Med (1996) 0.92
Probing enhanced cytochrome P450 2B1/2 activity in rat hepatocyte spheroids through confocal laser scanning microscopy. Cell Transplant (2001) 0.92
Characterization of the three-compartment gel-entrapment porcine hepatocyte bioartificial liver. Cell Biol Toxicol (1997) 0.92